Envision Pharma Group (Envision) has appointed Richard “Rich” Gorman to the role of President, Strategic Consulting and member of the Executive Leadership Team.
Rich is a 30-year veteran of the life sciences industry and a respected leader with a track record of success in pharmaceutical commercialization. He is an experienced head of high-performing teams that build go-to-market strategies to deliver on business development and revenue generation goals.
Rich will be responsible for leading the Strategic Consulting business across Envision’s commercial, medical, and technology sectors. He will lead a team of scientific, medical, and commercial strategists with deep expertise in the life sciences industry while combining its technology and AI platforms to accelerate the business and scientific momentum of clients’ strategies.
Prior to joining Envision, Rich served as Chief Commercial Officer and Global Head of Strategy for Amplity Health. Before that, he held various leadership positions and senior business development roles at Syneos Health. His background includes serving as a CEO for a specialty pharmaceutical company, as well as several positions within the field of contract pharmaceutical development and manufacturing.
Rich shares, “I am delighted to be joining Envision Pharma Group at this pivotal and exciting time. I am honored to have the opportunity to lead this talented team of strategy consultants. Combining their proven capabilities with the Envision technology platform will create a powerful option for manufacturers looking to efficiently bring new science and products to patients.”
Meg Heim, Chief Executive Officer of Envision Pharma Group states, “We are so excited to have Rich join our team as we continue to accelerate Envision’s business expansion, mission, and commitment to our clients’ needs. Rich’s proven expertise will be critical in partnering with our clients to execute upon their goals, improve performance, and meet their unique business needs with the support of our technology platforms and strategic advisory expertise.”
CloseEnvision Pharma Group (“Envision”), a leading Medical Affairs-focused scientific communications and technology solutions provider, is pleased to announce that Datavision − the industry-leading software solution for strategic publication planning – will now feature citation counts provided by Scopus
Envision Pharma Group (“Envision”), a leading Medical Affairs-focused scientific communications and technology solutions provider, announced today that Library – Envision’s searchable content management system for Medical Affairs materials, including publications and multimedia – will now feature attention data provided by data science company Altmetric
Envision Pharma Group offices have successfully obtained certification to International Standard Organization (ISO)/IEC 27001.
ISO 27001 is the international standard for cyber security. By attaining this certification, Envision have demonstrated a clear commitment to Information Security Management to third-parties and stakeholders, providing a process and framework to ensure the fulfilment of commercial, contractual and legal responsibilities, and providing for a common security approach within the Envision business units and a formal basis for inter-operability between Envision and its customers.
ISO Certification is obtained only after a rigorous external audit process and our global locations comprising Horsham in the UK, Southport, Glastonbury, Madison, Philadelphia in the US along with Sydney in Australia are now ISOQAR Registered and carry the Certificate Number 14800.
Envision is committed to the policy for the ongoing development and continual improvement of our information security management systems, therefore, meeting the strict requirements of ISO 27001.
Our Information Security Policy applies to all Envision systems and information, and is one of our key values as an organisation – trust. Envision adheres to the highest ethical standards, we keep our promises and we aspire to create open, honest working relationships.
ISO develops standards, accepted as preeminent in over 140 countries including the USA, Australia, Japan and the UK. These standards facilitate international exchange of goods and services, support sustainable and equitable economic growth, promote innovation and protect health, safety and the environment.
CloseDatavision® facilitates the compliant and transparent management of publication planning and delivery; the automated capture of various internal metrics (eg, time to submission, review times, approval times) allows the identification of inefficiencies and the optimization of the publication development process.
However, assessment of the ‘effectiveness’ or ‘impact’ of a publication often relies on the use of external metrics; a traditional measure of impact of a publication is the volume of citations in peer-reviewed literature. Envision has partnered with Scopus, a trusted provider of citation data, to ensure that Datavision records do not end at publication and that citation counts can be available for all publications tracked within the system.
Citation counts will be available to all Datavision users, with full details of the citing articles available via click-through to the Scopus system (available using an active Scopus subscription).
Russell Traynor, Envision’s Platform Director for iEnvision and former chair of the International Society of Medical Publication Professionals noted: “Citation metrics provide an invaluable benchmark for assessing the value and rigor of a piece of research. We are excited to be partnering with Scopus, as a leading provider of citation data, to bring this benchmarking ability to our global community of Datavision users.”
Russell added: “We are excited by this collaboration and hope that the addition of citations as an external measure of ‘impact’ will allow better assessment and optimization of the effectiveness of publication programs.”
For further information, please contact: Synnove Smeets (Synnove.Smeets@EnvisionPharmaGroup.com) or Russell Traynor (Russell.Traynor@EnvisionPharmaGroup.com).
Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies.
Envision is a leading provider of evidence communication services and industry-leading, technology solutions that have applicability across areas of Medical Affairs responsibility.
Under consistent leadership, Envision has grown steadily across its three core business areas in support of Medical Affairs:
Evidence Communication—including strategic publication planning, data dissemination services, medical education, and Market Access communications;
Technology Solutions—design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including: publication planning and management (Datavision), clearance and approval (Clear®), activity request and evidence generation management (Visiontracker®), workflow management for Health Economics and Outcomes Research activities (Visiontracker HEOR™), workflow management for Early Access Program activities (Visiontracker EAP™), searchable repository for the appropriate sharing of scientific content (Library™), and a next-generation solution for managing medical information enquiries (Medinfo™); and
Operational Excellence—policy, process, and compliance support and consultancy for Medical Affairs.
Envision has twelve offices: four in the United Kingdom – Horsham, Wilmslow, Marlow, and London; six in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT, and New York, NY; and two in the Asia-Pacific region – Tokyo and Sydney. The company employs 550 team members, including more than 200 highly qualified and experienced in-house medical writers and more than 100 technology solutions team members who provide software development and customer support. Envision provides services and technology solutions to more than 75 companies, including 19 of the top 20 pharmaceutical companies.
Launched in 2004 by Elsevier, Scopus is used by thousands of academic, government and corporate organizations to detect trends, find partnerships and identify experts to stay on the cutting edge of research. Combining the world’s largest abstract and citation database of peer-reviewed literature with smart tools to track, analyze and visualize research, Scopus is the tool to use if you need to keep track of global science.
Subscription pricing for Scopus varies according to the size of your organization. For more information about Scopus and subscription options, visit https://www.elsevier.com/solutions/scopus
CloseThe ‘impact’ of a peer-reviewed publication is an integral part of the assessment of the effectiveness of an individual publication or cumulatively, of a publication plan. While citations have long been considered the standard measure of publication impact, they may on occasions take months or years to emerge.
The shift to an online publication environment and the rise of social media have allowed the real-time assessment of indicators of dissemination (eg, via Twitter), interest (eg, news coverage), and readership (eg, Mendeley). Envision has partnered with Altmetric, the leading provider of such metrics, to facilitate access to these informative data via the Library content management solution – part of the expanding iEnvision suite of medical project management software solutions.
Fully integrated into the publication details held within Library, Altmetric badges and associated attention scores provide constantly updated, at-a-glance indicators of the engagement relating to published articles, and permit click-through-access to the Altmetric.com website for more detailed information on the demographic, geographic, and contextual nature of these data please see Altmetric links below.
Library is built on the iEnvision™ Medical Project Management platform, purpose-built to meet the needs of Medical Affairs and related functions. Library can be fully integrated with current versions of Datavision® (publications management), as well as other third-party and corporate applications.
Russell Traynor, Envision’s Platform Director for iEnvision and former chair of the International Society of Medical Publication Professionals noted: “We are excited to announce this collaboration and hope that the addition of Altmetric data to Library will provide additional insights and value to the users of our solutions.”
Catherine Williams, Chief Marketing Officer, of Altmetric commented: “We’re really pleased to see Envision integrating our data and badges into the Library platform. The attention insights provided will be useful for pharmaceutical companies and communications agencies in assessing the performance of their own publications as well as those of their competitors, and will be a powerful tool for more informed strategic planning.”
For further information, please contact: Synnove Smeets (Synnove.Smeets@EnvisionPharmaGroup.com) or Russell Traynor (Russell.Traynor@EnvisionPharmaGroup.com).
Follow us on Twitter – @EnvisionPharma – or LinkedIn for company updates
Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies.
Envision is a leading provider of evidence communication services and industry-leading, technology solutions that have applicability across areas of Medical Affairs responsibility.
Under consistent leadership, Envision has grown steadily across its three core business areas in support of Medical Affairs:
Evidence Communication—including strategic publication planning, data dissemination services, medical education, and Market Access communications;
Technology Solutions—design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including: publication planning and management (Datavision®), clearance and approval (Clear®), activity request and evidence generation management (Visiontracker®), workflow management for Health Economics and Outcomes Research activities (Visiontracker HEOR™), workflow management for Early Access Program activities (Visiontracker EAP™), searchable repository for the appropriate sharing of scientific content (Library™), and a next-generation solution for managing medical information enquiries (Medinfo™); and;
Operational Excellence—policy, process, and compliance support and consultancy for Medical Affairs.
Envision has twelve offices: four in the United Kingdom – Horsham, Wilmslow, Marlow, and London; six in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT, and New York, NY; and two in the Asia-Pacific region – Tokyo and Sydney. The company employs 550 team members, including more than 200 highly qualified and experienced in-house medical writers and more than 100 technology solutions team members who provide software development and customer support. Envision provides services and technology solutions to more than 75 companies, including 19 of the top 20 pharmaceutical companies.
Altmetric was founded in 2011 and has made it a mission to track and analyze the online activity around scholarly literature. It collates what people are saying about published research outputs in sources such as the mainstream media, policy documents, social networks, blogs, and other scholarly and non-scholarly forums to provide a more robust picture of the influence and reach of scholarly work. Altmetric works with some of the biggest publishers, funders, and institutions around the world to deliver this data in an accessible and reliable format.
Altmetric is supported by Digital Science – a technology company that combines world-class technology with a resolute focus on scientists and those who support the research process. Find out more at altmetric.com and follow us on Twitter @altmetric.
Digital Science is a technology company serving the needs of scientific and research communities, at the laboratory bench or in a research setting. It invests in and incubates scientific software companies that simplify the research cycle, making more time for discovery. Its portfolio companies and investments include a host of leading and admired brands including Altmetric, BioRAFT, Figshare, GRID, Labguru, Peerwith, Overleaf, ReadCube, Symplectic, TetraScience, Transcriptic, and ÜberResearch. It is operated by global media company, the Holtzbrinck Publishing Group. Visit http://www.digital-science.com and follow @digitalsci on Twitter.
Close
Envision Pharma Group (“Envision”), a leading Medical Affairs-focused scientific communications and technology solutions provider, is pleased to announce the launch of Medinfo™
Envision Pharma Group (“Envision”), a leading Medical Affairs-focused scientific communications and technology solutions provider, has acquired Curo Consulting Ltd
Envision Pharma Group presented original research at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – Sheraton Boston Hotel and the John B. Hynes Veterans Memorial Convention Center, Boston, MA, USA, May 20−24, 2017
Medinfo is a complete, globally scalable solution that transparently and compliantly manages the provision of medical information to healthcare professionals, patients, caregivers, and other enquirers. Medinfo is currently being implemented at several companies.
Medinfo is built on the iEnvision™ platform and is part of the integrated suite of iEnvision solutions, purpose-built to meet the needs of Medical Affairs and related functions. Medinfo can be fully integrated with other iEnvision solutions such as Datavision® (publications management), Library™ (scientific content asset management), and Clear® (system-managed clearance and approval processing), as well as other third-party and corporate applications including CRM, other CMS, pharmacovigilance, and product quality systems.
Validation, audit, and transparency reporting requirements are a key aspect, with standard Medinfo implementations being validated to Software Validation Process 21 CFR Part 11 Compliant GxP Standards. Further client-configured validation support is available.
Medinfo was developed in-house at Envision as a specific medical information solution under the guidance of a team of senior medical information specialists with over 35 years cumulative experience in hands-on, industry-based medical information roles. This was combined with Envision’s 15-year experience in providing medical request- and scientific communications-related technology solutions to create a robust, advanced, and purpose-specific solution for medical information needs.
Medinfo provides a next generation medical information solution comprising multichannel request intake using an integrated web portal, streamlined and simplified enquiry management processing with adverse event and product quality intake capabilities, system-suggested response generation support, and robust content creation and management facilities. Built-in analytical features including dashboards, metrics, and reporting enable insights to be captured, this in turn, can inform and improve response quality, as well as future data and evidence generation requirements. Medinfo quickly and efficiently helps get the right answer to the enquirer and enables actionable insights to improve future responses. In addition, the Operational Excellence Consulting arm of Envision is able to provide complementary standard response medical writing and implementation support services.
For further information, please contact: Kelli Walker (kelli.walker@EnvisionPharmaGroup.com) or Russell Traynor (Russell.Traynor@EnvisionPharmaGroup.com).
Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies.
Envision is a leading provider of evidence communication services and industry-leading, technology solutions that have applicability across areas of Medical Affairs responsibility.
Under consistent leadership, Envision has grown steadily across its three core business areas in support of Medical Affairs:
(i) Evidence Communication—including strategic publication planning, data dissemination services, medical education, and Market Access communications;
(ii) Technology Solutions—design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including: publication planning and management (Datavision®), clearance and approval (Clear®), activity request and evidence generation management (Visiontracker®), workflow management for Health Economics and Outcomes Research activities (Visiontracker HEOR™), workflow management for Early Access Program activities (Visiontracker EAP™), searchable repository for the appropriate sharing of scientific content (Library™), and a next-generation solution for managing medical information enquiries (Medinfo™); and
(iii) Operational Excellence—policy, process, and compliance support and consultancy for Medical Affairs.
Envision has 12 offices: four in the United Kingdom – Horsham, Wilmslow, Marlow, and London; six in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT, and New York, NY; and two in the Asia-Pacific region – Tokyo and Sydney. The company employs 520 team members, including more than 200 highly qualified and experienced in-house medical writers and more than 100 technology solutions team members who provide software development and customer support. Envision provides services and technology solutions to more than 75 companies, including 19 of the top 20 pharmaceutical companies.
Close
Curo specializes in enabling biopharma companies to communicate with payers, policy makers, and providers ‘in their language’ and notably, Curo won the Queen’s Award for Enterprise – International Trade in 2015, the UK’s highest accolade for business success. Curo’s Chairman, Jonathan Mowll, and CEO, Christopher O’Neill, will continue to drive Curo’s operations and will join Envision’s management team.
The acquisition was supported by Envision’s equity partners – Ardian, the independent private investment company, and GHO Capital, the specialist European investor in healthcare. Additional terms of the transaction were not disclosed.
Operating globally, Envision is a leading partner to Medical Affairs organizations, providing scientific data communication services and industry standard technology solutions to biopharmaceutical and medical device companies.
Envision’s unique position within the growing market of outsourced Medical Affairs services, including value-oriented communications, is underpinned by integrating scientific and industry expertise with a range of purpose-built technology solutions that facilitate planning, knowledge-sharing, operational excellence, and decision-making.
Curo’s core skill set in creating effective Market Access strategies, delivered in an innovative and compelling manner, will bolster Envision’s existing Market Access solutions and complement the group’s wider range of services – including medical writing, publication planning, medical communications, and operational excellence consultancy.
Similarly, Curo’s HEOR and Market Access software will complement Envision’s extensive range of industry-leading technology solutions (Datavision®, Library™, Visiontracker®, Clear®, Medinfo™ and Visiontracker HEOR™). Curo’s state-of-the-art applications – LENS™, which dynamically matches key data sets with payer needs, and Evidence Navigator™, which facilitates value narratives tailored to the needs of different payer archetypes – will be valuable additions to Envision’s range of technology solutions and provide an essential toolkit for our Market Access clients.
Envision's CEO, Brian Hepburn, commented, "The addition of Curo to the Envision Pharma Group augments our existing Market Access capabilities and further cements our core tenet of marrying expertise and technology to become the leading international Medical Affairs agency. In the current biopharma landscape, value demonstration is an essential part of the evidence communication package. Curo’s consulting expertise and software products will ensure that we offer optimal evidence communication strategies to our clients.”
Curo CEO, Christopher O’Neill, stated, “We are absolutely delighted to become part of Envision. Curo has spent the past 3 years building and proving the impact of a series of innovative digital platforms to support Value Curation in HEOR and Market Access. In Envision, we have found a partner with the same commitment to combining services with supporting technology. Philosophically, this is incredibly important. Practically, the size and reach of the Envision group will give us the opportunity to build out a scalable infrastructure which will enable us to service our clients with more comprehensive end-to-end Value Curation solutions.”
Founded in 2001, Envision Pharma is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology, and medical device companies. Initially focusing on re-inventing the way biopharma companies managed their global data communications programs through the use of smart technology and best-in-class publication planning, Envision has evolved to become a leading provider of evidence communication services and Medical Affairs solutions encompassing all aspects of scientifically driven data dissemination activities required to support a successful access to market strategy for new biopharma compounds.
This capability of the organization is further enhanced with industry-leading, complementary technology solutions across the Medical Affairs responsibilities. Envision has grown steadily under consistent leadership across its three core business areas in support of the Medical Affairs team that include (i) Evidence Communication – including strategic publication planning, data dissemination services, medical education, and Market Access communications; (ii) Technology Solutions – design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including, publication planning and management (Datavision®), clearance approval (Clear®), activity request management (Visiontracker®), workflow management for HEOR activities (Visiontracker HEORTM), searchable repository for the sharing of appropriate educational and training materials (LibraryTM), and next-generation solution for managing medical information enquiries (MedinfoTM); (iii) Consulting Solutions – policy, process, compliance, and guideline consultancy to life-science companies.
Envision currently has ten offices, three in the United Kingdom – Horsham, Wilmslow, and London; five in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT; and two in Asia Pacific – Tokyo and Sydney. The company employs approximately 500 team members, including over 200 highly qualified and experienced in-house medical writers and a more than 80-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 18 of the top 20 pharmaceutical companies.
With over a decade’s experience in the wider consulting industry, Curo offers a new perspective and a different approach to Market Access. Well respected in the industry, we pride ourselves on thinking beyond the usual parameters of the pharma world. True, we have a team of Health Economics experts and specialist software builders, but we are not data processors, nor a software company. Instead, we use our resources to build narratives that speak to Payers and answer their questions; helping you to show that it is value that matters, not cost. Curo are also proud winners of The Queen’s Award for Enterprise – International Trade, 2015, the UK’s highest accolade for business success.
Ardian, founded in 1996 and led by Dominique Senequier, is an independent private investment company with assets of US$55bn managed or advised in Europe, North America, or Asia. The company, which is majority-owned by its employees, keeps entrepreneurship at its heart and delivers investment performance to its global investors while fuelling growth in economies across the world. Ardian’s investment process embodies three values: excellence, loyalty, and entrepreneurship.
Ardian maintains a truly global network, with more than 410 employees working through twelve offices in Paris, London, Frankfurt, Milan, Madrid, Zurich, New York, San Francisco, Beijing, Singapore, Jersey, and Luxembourg. The company offers its 470 investors a diversified choice of funds covering the full range of asset classes through Ardian Direct Funds (comprising Ardian Mid Cap Buyout, Ardian Expansion, Ardian Growth, and Ardian Co-Investment), Ardian Infrastructure, Ardian Funds of Funds (comprising primary, early secondary, and secondary activities), Ardian Private Debt, Ardian Real Estate, and customized mandate investment solutions with Ardian Mandates.
Global Healthcare Opportunities, or GHO Capital Partners LLP, was founded in 2014 as a specialist healthcare investment adviser based in London. Its vision is to apply global capabilities and perspectives to build a world-class healthcare specialist private equity firm by recognising and seizing the highly attractive and underpenetrated European market opportunity. GHO Capital has a powerful combination of transaction, investment, and industry skills which sets it apart from traditional private equity firms. For further information, please visit www.ghocapital.com.
Contact: Trevor Fitzpatrick - Trevor.Fitzpatrick@EnvisionPharmaGroup.com
Close
Members of Envision’s Market Access Solutions team and their co-authors presented new insights on the important issue of biosimilar uptake and use in the USA.
Both presentations took place in Research Poster Presentations – Session II was on Monday, May 22nd (3:45-7:45pm), with an Author Discussion Hour between 6:45pm and 7:45pm.
Envision’s Karen Smoyer, PhD and Bríain Ó Hartaigh, PhD presented research on the “Uptake of the First US Biosimilar: Filgrastim-sndz Utilization Observed in a Medical Transcription Database of Patient Office Visits”.
Envision’s Karen Smoyer, PhD and Trevor Fitzpatrick, CMPP presented research conducted in collaboration with Cardinal Health on the “Initial Uptake and Utilization Patterns of Filgrastim-sndz, the First US Biosimilar”.
The theme of this year’s meeting was “Evidence and Value in a Time of Social and Policy Change” and full details of the agenda can be found here or via the meeting App for iOS or ANDROID devices.
Events were followed in Boston on Twitter using #ISPORBoston
CloseEnvision Pharma Group (“Envision”), a highly successful Medical Affairs-focused, technology-enabled scientific communications company is delighted to announce two new roles within our leadership team
Ardian, the independent private investment company, in collaboration with GHO Capital, the specialist European investor in healthcare, has partnered with the Envision Pharma Group’s (“Envision”) leadership team to acquire Envision, a leading Medical Affairs-focused scientific communications and technology solutions provider, from the Halifax Group. The management team and employees, led by Brian Hepburn (CEO and founder), Greg Caswill (Chairman and founder), John Gillie (CFO), and Joseph Brown (President Envision Technology Solutions; ETS), will be reinvesting and continuing to lead the business in the next evolution of its growth
Envision Pharma Group (“Envision”), a highly successful Medical Affairs-focused, technology-enabled scientific communications company is delighted to announce that Anne Clare Wadsworth has joined the Envision management team
Dr Joseph Kohles will assume the position of Chief Medical Officer (CMO) to provide medical leadership across the group, provide direction for the development of medical strategy for our clients, provide a peer-to-peer contact for our Medical Affairs clients, and aid in the development/optimization of new technology solutions to support our expanding range of Medical Affairs services. Joe will also head-up a Medical Strategy “think tank” within Envision to provide our clients with leading-edge solutions to the changing demands of the Medical Affairs team and the environment in which they operate.
David Thompson will assume the position of Chief Strategy Officer (CSO) to help drive Envision's continued growth into the leading, global Medical Affairs agency, incorporating expanded multichannel medical communications capabilities, and oversee our expansion into appropriate global locations to facilitate closer proximity to our client base. David will also ensure the continued and improved synergy between our scientific services and supporting technology solutions to maintain Envision’s position as the only medical communications company that encompasses world-class scientific expertise, supported by industry-leading technology solutions to compliantly deliver multichannel medical communication programs. Although responsible for ensuring effective delivery of our scientific services across all 10 of our current global offices, David will be relocating to the UK as part of his new role, and will be based out of our Horsham office for alignment with the existing operational leadership team.
The current leadership team Brian Hepburn (CEO), Greg Caswill (Chairman), Joe Brown (President of Envision Technology Solutions) and John Gillie (CFO) will remain in their existing positions and welcome the augmented structure of leadership team as Envision continue their expansion.
Brian Hepburn, commented, “David and Joe bring incremental strength and depth to the management team, further extending our capabilities and expertise and enhancing our objective of becoming the comprehensive strategic partner to the Medical Affairs departments of our extensive client base.”
Envision Pharma Group are still recruiting for open positions at all levels across the organization – https://www.envisionpharmagroup.com/careers.
For an informal discussion, or to apply for any of these roles, please contact Karen Kent (Envision Pharma Group Recruiter – Karen.Kent@EnvisionPharmaGroup.com).
Founded in 2001, Envision Pharma Group is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology, and medical device companies. Initially focusing on re-inventing the way biopharma companies managed their global data communications programs through the use of smart technology and best-in-class publication planning; Envision has evolved to become a leading provider of evidence communication services and Medical Affairs solutions encompassing all aspects of scientifically-driven data dissemination activities required to support a successful access to market strategy for new biopharma compounds.
This capability of the organization is further enhanced with industry-leading, complementary technology solutions across the Medical Affairs responsibilities. Envision has grown steadily under consistent leadership across its three core business areas in support of the Medical Affairs team that include (i) Evidence Communication – including strategic publication planning, data dissemination services, medical education, and Market Access communications; (ii) Technology Solutions – design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including, publication planning and management (Datavision®), clearance approval (Clear®), activity request management (Visiontracker®), workflow management for HEOR activities (Visiontracker HEORTM), searchable repository for the sharing of appropriate educational and training materials (LibraryTM), and next generation solution for managing medical information enquiries (MedinfoTM); (iii) Consulting Solutions – policy, process, compliance, and guideline consultancy to life-science companies.
Envision currently has ten offices, three in the United Kingdom – Horsham, Wilmslow, and London; five in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT; and two in Asia Pacific – Tokyo and Sydney. The company employs approximately 450 team members, including over 185 highly qualified and experienced in-house medical writers and a more than 80-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 18 of the top 20 pharmaceutical companies.
CloseOperating globally, Envision is a recognized partner to the Medical Affairs organizations providing scientific data communication services and industry-leading technology solutions to biopharmaceutical and medical devices companies on a global basis. Envision assists its clients in supporting the commercialization of new compounds via strategic data-communication planning, medical writing, medical communications services, and providing best-in-class technology solutions across the key operational functions of Medical Affairs.
Since inception in 2001, Envision has enjoyed strong year-on-year organic growth of c.20%. In addition to this organic growth, Envision has recently made two strategic acquisitions: ProScribe − extending their global reach into the Asia-Pacific region; and the Alligent Group − expanding their range of medical communication services to fully support their data continuum strategy across Medical Affairs functions. Envision has also launched several new solutions, including: Medical Information, HEOR Portfolio Management, and the Medical Affairs Library, which enhance the suite of solutions focused on Medical Affairs operational excellence.
These acquisitions and solution expansions further bolster Envision’s capabilities and build upon the range of service and solution offerings, which, in addition to publication planning and delivery, have grown to encompass medical strategy consultancy, Market Access communications, medical communications & MSL support, digital and creative services, and policy and operational excellence consultancy.
Envision’s unique position within the growing market of outsourced Medical Affairs services is underpinned by seamlessly marrying unparalleled scientific and industry expertise with a range of purpose-built, technology solutions that facilitate knowledge-sharing, operational excellence and decision-making effectiveness.
Datavision® is the industry standard solution for compliant publication planning, execution and management. However, the range of innovative and strategic management software, purpose-built for life-science clients has also expanded to provide support for our newer service offerings in Medical Affairs and Market Access:
In line with our goal to facilitate efficient knowledge-sharing, operational excellence, and decision-making capabilities across Medical Affairs and executives in global life-science organizations, we are launching the new iEnvisionTM Medical Affairs platform. The primary objective of iEnvisionTM is to provide a suite of purpose-built solutions to facilitate/support industry best practice within the Medical Affairs organization. The iEnvisionTM suite enables effective communication and monitoring of the plans, consistency for reporting and KPI metrics, and establishes consistent and auditable controls for compliance purposes. Our new Library™ and Medinfo™ solutions are available now, and our existing classic solutions are being moved to the platform during 2016 (Visiontracker®) and 2017 (Datavision® and Clear®), with additional complementary solutions already being designed.
Regarding the importance of the iEnvisionTM platform, Joseph Brown, President of ETS, said “The iEnvisionTM platform and modules, through collaboration with our client partners, is a cornerstone to help support the future Medical Affairs operational model. iEnvisionTM will enhance a Medical Affairs team’s efficiency and quality, improve global effectiveness and alignment by connecting HQ and country operations, reduce costs by improving global scalability and facilitating the concept of a Medical Affairs center of excellence, and improve overall decision-making by creating a ‘data forward’ line of sight across Medical Affairs. The partnership with Ardian and GHO enables us to enhance our already significant investment in the platform in terms of both transitioning our existing solutions to iEnvisionTM and bringing additional new solutions, purpose-built to support Medical Affairs business needs, to market in a timely and efficient manner.”
Brian Hepburn, CEO of Envision, said “This partnership with Ardian and GHO Capital provides the resources, expertise, and market knowledge for Envision to realize the next stage of its development and become the leading solution provider to the Medical Affairs departments within the biopharmaceutical industry. We are uniquely positioned to support our clients via our in-depth, strategically focused, scientific communication capabilities in combination with our expanding range of technology solutions that support compliant and transparent communication of scientific evidence. With the support of Ardian and GHO Capital, we will continue to invest in these core competencies and further extend the market reach of our enterprise technology platform, iEnvisionTM.”
Simon Cottle, Managing Director of Ardian Mid Cap Buyout in London, said “After analyzing the outsourced Medical Affairs services and software market, we identified Envision as having the highest potential for further growth. Their management team has done a great job in creating a market-leading proposition and we look forward to working with them in the next stage of the business’ development.”
Bruno Ladriere, Managing Director of Ardian Mid Cap Buyout in London, added “We believe that Ardian’s transparent management-centric culture, coupled with our global ability to support development through organic and external growth, were the key elements in winning the support of Envision’s management and executing this acquisition.”
Mark Branganza, Partner at GHO Capital, added “Envision is a high growth company operating in the attractive healthcare outsourced services sub-sector with a strong platform and an international, blue-chip customer base. The opportunity to partner with Ardian and the management team, allowing us to pool our significant expertise in consulting and healthcare IT, was therefore extremely compelling for our fund. We look forward to our partnership in supporting the next phase of Envision’s continued growth.”
Founded in 2001, Envision Pharma is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology, and medical device companies. Initially focusing on re-inventing the way biopharma companies managed their global data communications programs through the use of smart technology and best-in-class publication planning; Envision has evolved to become a leading provider of evidence communication services and Medical Affairs solutions encompassing all aspects of scientifically driven data dissemination activities required to support a successful access to market strategy for new biopharma compounds.
This capability of the organization is further enhanced with industry-leading, complementary technology solutions across the Medical Affairs responsibilities. Envision has grown steadily under consistent leadership across its three core business areas in support of the Medical Affairs team that include (i) Evidence Communication – including strategic publication planning, data dissemination services, medical education, and Market Access communications; (ii) Technology Solutions – design, development, implementation, and support of innovative and strategic management software, purpose-built for life-science clients, including, publication planning and management (Datavision®), clearance approval (Clear®), activity request management (Visiontracker®), workflow management for HEOR activities (Visiontracker HEORTM), searchable repository for the sharing of appropriate educational and training materials (LibraryTM), and next generation solution for managing medical information enquiries (MedinfoTM); (iii) Consulting Solutions – policy, process, compliance, and guideline consultancy to life-science companies.
Envision currently has ten offices, three in the United Kingdom – Horsham, Wilmslow, and London; five in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT; and two in Asia Pacific – Tokyo and Sydney. The company employs approximately 450 team members, including over 185 highly qualified and experienced in-house medical writers and a more than 80-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 18 of the top 20 pharmaceutical companies.
Ardian, founded in 1996 and led by Dominique Senequier, is an independent private investment company with assets of US$55bn managed or advised in Europe, North America, or Asia. The company, which is majority-owned by its employees, keeps entrepreneurship at its heart and delivers investment performance to its global investors while fuelling growth in economies across the world. Ardian’s investment process embodies three values: excellence, loyalty, and entrepreneurship.
Ardian maintains a truly global network, with more than 410 employees working through twelve offices in Paris, London, Frankfurt, Milan, Madrid, Zurich, New York, San Francisco, Beijing, Singapore, Jersey, and Luxembourg. The company offers its 470 investors a diversified choice of funds covering the full range of asset classes through Ardian Direct Funds (comprising Ardian Mid Cap Buyout, Ardian Expansion, Ardian Growth, and Ardian Co-Investment), Ardian Infrastructure, Ardian Funds of Funds (comprising primary, early secondary, and secondary activities), Ardian Private Debt, Ardian Real Estate, and customized mandate investment solutions with Ardian Mandates.
Global Healthcare Opportunities, or GHO Capital Partners LLP, was founded in 2014 as a specialist healthcare investment adviser based in London. Its vision is to apply global capabilities and perspectives to build a world-class healthcare specialist private equity firm by recognising and seizing the highly attractive and underpenetrated European market opportunity. GHO Capital has a powerful combination of transaction, investment, and industry skills which sets it apart from traditional private equity firms. For further information please visit www.ghocapital.com.
Anne Clare joins the Envision management team that oversees operations in Wilmslow, and across our nine other offices in the UK, US, and Asia-Pacific. As part of our continued expansion, Wilmslow, will serve as a North West office for the expansion of Envision’s core services and will also act as a head office for the Alligent Group’s (“Alligent”) European operations. Alligent, a leading Medical Affairs agency that develops and delivers strategically focused, integrated and aligned medical communications solutions to the biopharma industry, became part of the Envision Pharma Group in September, 2015.
Envision’s CEO, Brian Hepburn, commented, “The new office in Wilmslow not only provides a base for Alligent’s European operations, but continues Envision’s structured expansion with an office in the North West of England, a traditional centre of excellence for medical communications. The new location, coupled with Anne Clare’s leadership capabilities and client-centric approach, will help drive the continued expansion of Envision’s service line capabilities while establishing Alligent’s European operations as this business unit continues to thrive.”
Alligent Group founders, David Thompson and Joe Kohles, added, “We are delighted to open our Wilmslow office with such a well-recognized and vastly experienced medical communications leader in Anne Clare. Under her stewardship we are confident Envision’s North West footprint will grow rapidly as a centre of excellence for the industry’s brightest talent as well as serve as a commercial hub for Alligent's thriving European medical strategy business.”
The Envision Pharma Group, including the Alligent European team, are still recruiting for open positions at the level of Scientific Director, Medical Writer (all levels), Account Manager and Account Director.
For an informal discussion, or to apply for any of these roles, please contact Karen Kent (Envision Pharma Group Recruiter – Karen.Kent@EnvisionPharmaGroup.com) or Anne Clare Wadsworth (Head of Alligent Europe − Anne-Clare.Wadsworth@EnvisionPharmaGroup.com).
Founded in 2001, Envision Pharma Group is an international, innovative, global technology and scientific communication company serving the medical affairs requirements of pharmaceutical, biotechnology, and medical device companies. Initially focusing on publication planning, Envision has evolved to become a leading provider of evidence-based communication services, encompassing all aspects of scientifically driven data dissemination activities required to support a successful “access to market strategy” for new biopharma products.
This capability of the organization is further enhanced with industry-leading, complementary technology solutions. Envision has grown steadily under consistent leadership across its three core business areas in support of the Medical Affairs Team that include (i) Evidence Communication – including strategic publication planning, data dissemination services, Med Ed and market access communications; (ii) Technology Solutions – design, development, implementation, and support of innovative and strategic management software purpose-built for life-science clients including publication planning and management (Datavision®), clearance approval (Clear®), activity request management (Visiontracker®), workflow management for HEOR activities (Visiontracker HEORTM), searchable repository for the sharing of appropriate educational and training materials (LibraryTM), and next generation solution for managing medical enquiries (MedinfoTM); (iii) Consulting Solutions – policy, process, compliance, and guideline consultancy to life-science companies.
Envision currently has ten offices, three in the United Kingdom – Horsham, Wilmslow and London; five in the United States – Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ, Glastonbury, CT; and two in Asia-Pacific – Tokyo and Sydney. The company employs approximately 460 team members, including over 185 highly qualified and experienced in-house medical writers and a more than 70-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 18 of the top 20 pharmaceutical companies.
Alligent was acquired by the Envision Pharma Group in September, 2015. Alligent was built to support the strategic and tactical needs of our clients’ medical directors and currently provides strategic medical planning and program implementation for the Medical Affairs Departments of a number of leading biopharma organizations. Based in Stirling, NJ, the company employs over 50 communications and scientific experts with extensive industry and agency experience, particularly within the area of oncology.
CloseEnvision Pharma Group (“Envision”), an innovative, technology-enabled scientific communications company focused on the biopharma and medical device industries, announced today that it has acquired Alligent Biopharm Consulting LLC (”Alligent”). Alligent is a leading Medical Affairs agency that develops and delivers strategically-focused, integrated and aligned medical communications solutions to the biopharma industry. The deal was supported by the Halifax Group, a leading private equity firm which invests in health and biopharma services businesses, partnering with the Envision management team to provide the equity investment to facilitate the acquisition. Additional terms of the transaction were not disclosed
Young investigators, defined as physicians in fellowship training or junior faculty positions, are at a critical stage in their academic development and benefit from advice from leading researchers in their therapeutic specialty area
Envision Pharma Group, engaged by 18 of the top 20 pharma companies to support their Medical Affairs teams and to provide industry-leading software, has made a significant new investment
Alligent’s core skill sets of medical strategy development and planning, allied program implementation and stakeholder support will complement Envision’s existing services of strategic data dissemination – including publication planning, consultancy, and market access communications – to provide global Medical Affairs Departments with compliant, strategically focused evidence communication programs. Underpinning its services, the expanded Envision Pharma Group will continue to provide its expansive client base with industry leading technology including Datavision®, Visiontracker®, Clear™ and Medinfo™. Alligent’s two principals, Joe Kohles and David Thompson, will also be joining the Envision Pharma Leadership team.
Envision's CEO, Brian Hepburn, commented, "The addition of Alligent to the Envision Pharma Group further cements our core tenet of becoming the leading international medical affairs agency. By acquiring Alligent, we are able to expand the capabilities we offer to medical affairs teams to ensure optimal evidence communication and ultimate product adoption based on scientific rigor.”
Messrs. Kohles and Thompson stated, “We are delighted to join the Envision Pharma Group. Our focus on medical strategy, coupled with Envision’s global presence and technology leadership position, offers the potential for us to expand and enrich our service breadth and offering to current and future clients alike. We look forward to joining the Group’s leadership team and contributing to the continued success of both Alligent and Envision.”
“The addition of the Alligent team is truly complimentary to the Envision Pharma group. We believe their combined capabilities will further enhance Envision’s ability to optimize the communication of complex scientific data on behalf of their clients, which will be of ultimate benefit to health care providers, payors and patients," added Halifax principal Scott Plumridge.
Founded in 2001, Envision Pharma is an international, innovative global technology and scientific communication company serving pharmaceutical, biotechnology and medical device companies. Initially focusing on publication planning Envision has evolved to become a leading provider of evidence communication services encompassing all aspects of scientifically driven data dissemination activities required to support a successful access to market strategy for new biopharma compounds.
This capability of the organization is further enhanced with industry leading complementary technology solutions. Envision has grown steadily under consistent leadership across its three core business areas that include (i) Evidence Communication – including strategic publication planning, data dissemination services and market access communications; (ii) Technology Solutions - design, development, implementation and support of innovative and strategic management software for life sciences clients including publication planning and management (Datavision®), clearance approval (ClearTM), and activity request management (Visiontracker®); and (iii) Consulting Solutions – policy, process, compliance and guideline consultancy to life-science companies.
Envision has eight offices, two in the United Kingdom - Horsham and London, four in the United States including offices in Philadelphia, PA; Southport, CT; Madison, NJ and Glastonbury, CT and two in Asia Pacific -Tokyo and Sydney . The company employs approximately 380 team members, including over 160 highly qualified and experienced in-house medical writers and a 65-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 19 of the top 20 pharmaceutical companies.
Alligent was built to support the strategic and tactical needs of the medical director and currently provides strategic medical planning and program implementation for the medical affairs departments of a number of leading biopharma organizations. Based in Stirling, NJ, the company employs over 30 communications and scientific experts with extensive industry and agency experience, particularly within the area of oncology.
The Halifax Group is a private equity firm that partners with managers and entrepreneurs to recapitalize and grow lower middle-market businesses across a variety of industries including health and wellness, infrastructure, business and government services, and franchising. The firm maintains offices in Washington, D.C.; Dallas, TX; and Raleigh, NC. For more information, please visit www.thehalifaxgroup.com.
Contact:
Caroline Luz
Owen Blicksilver Public Relations, Inc.
203-656-2829
caroline@blicksilverpr.com
Close
ARC’s focus is on young investigators and programs that will assist these investigators in achieving success in their academic research career. The “Young Investigators’ Forum” (YIF) is ARC’s flagship program. YIF programs are non-commercial scientific research forums directed at young investigators with a goal of stimulating development of careers in academic research, a crucial area for improving patient management and outcomes.
Young investigators submit an abstract of their research based on specified criteria to a panel of expert faculty in a specific therapeutic area who then evaluate the research. The authors of the top research are selected to attend the YIF, where they present their research in full and the same expert faculty comment, question, give feedback and make suggestions to the young investigators on the research presented. The top presenters are awarded a grant to be used for their research. In addition, expert faculty provide career advice and experience-based presentations on selecting a mentor, acquiring grants, publishing research, achieving balance between work and family, and related topics. The support for all researchers and faculty to attend the YIF is provided through educational grants. Programs can be accredited for continuing medical education through Joint Providership Policies and Agreements with our educational partners. All accredited YIF activities are planned and implemented in accordance with the Accreditation Council for Continuing Medical Education (ACCME®) Essential Areas and policies as well as current reporting requirements.
Of note, many of the young investigators who are now recognized leaders in academic research positions have credited their career success in part to this learning experience.
For more information on ARC, please contact:
John A. Romankiewicz, Pharm D
Director, Young Investigator Programs
ARCoalition LLC
333 Main Street
Madison, NJ 07940
Tel: 973-443-3829
Email: John.Romankiewicz@ar-coalition.com
http://www.ar-coalition.com
To augment the acquisition of ProScribe made earlier in the year, Envision has established a new office in a prime location in Sydney, Australia. Commenting on the investment, Brian Hepburn, CEO said, “We are delighted to have made this strategic investment in the area, increasing our service capabilities with a new office in close proximity to a number of our key clients”.
Envision Pharma Group has employees in multiple offices in Europe, North America and the Asia-Pacific region. On Envision’s continued expansion, Brian noted that “With a strong history of unique and innovative publication and technology capabilities and our recent evolution into additional medical communications solutions, Envision Pharma Group is busier than ever. All our offices are growing as we continue to strengthen our support to more than 60 life sciences companies”.
Envision Pharma Group is seeing the growth in publication and overall medical communication programs matched by an increase in technology solutions, which now have over 120,000 individual users. Hepburn explained that, “the Group will continue to look to expand further, with other global offices likely to be established during the next 18 months”. Located in the Macquarie Park area of Northern Sydney, the office is approximately 12 km from Sydney’s central business district. Dr Mark Woolley, who heads up the new location said, “This presence further cements our Asia-Pacific capabilities and establishes us in a well recognised location within the region, with close proximity to a number of our key clients”.
ProScribe – Envision Pharma Group is located at:
Suite 1.01
Talavera Business Park
Level 1, 6‒10 Talavera Rd
Macquarie Park, NSW 2113
Australia
Tel: + 61 2 8058 4350
Fax: +61 2 8058 4352
For further information, please email either:
Alex Torre-Tasso: Alex.Torre-Tasso@EnvisionPharmaGroup.com
or
Karen Woolley: karen.woolley@EnvisionPharmaGroup.com.